萊美藥業(300006.SZ):公司法定代表人變更為彭偉民
格隆匯 9 月 4日丨萊美藥業(300006.SZ)公告,2020年6月12日召開的第五屆董事會第一次會議審議通過了《關於選舉公司董事長、副董事長的議案》,選舉彭偉民為公司第五屆董事會董事長。
根據《公司章程》的規定,董事長為公司法定代表人。近日公司完成了法定代表人工商登記變更手續,並換領了新的營業執照。
營業執照變更內容如下:
原法定代表人:邱宇
變更後法定代表人:彭偉民
除上述事項外,公司營業執照其他登記事項不變
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.